Attached files
| file | filename |
|---|---|
| EX-16.1 - M45 Mining Resources, Inc. | v196824_ex16-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): September 15,
2010
Neuro – Biotech
Corp.
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
|
33-55254-42
|
87-0485310
|
||
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
Aeschenvorstadt
71, CH-4051 Basel, Switzerland
|
||
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 41 61 500 05 16
M45 Mining Resources, Inc.,
4020 St-Ambroise, Suite 497, Montreal, Quebec Canada
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On
September 15, 2010 Mr. Barry Somervail resigned as the President, CEO and
Director of Neuro-Biotech Corp. (the “Company”). Mr. Somervail
decided to resign as a result of the Company’s new business ventures in the
field of neuroscience; however, he is not resigning as the result of a
disagreement on any matter relating to the Company’s operations, policies or
practices.
On
September 15, 2010 Mr. Claude Poulin was appointed the President and CEO of the
Company and elected Director. Mr. Poulin is 71 years of age, a
general practitioner with over 40 years of experience and has his own cabinet in
Lachute, Quebec Canada.
Item
9.01 Financial Statements and Exhibits.
Letter
from Mr. Barry Somervail.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereto
duly authorized.
Date:
September 16, 2010
NEURO-BIOTECH
CORP.
/s/
Michael Yamani
Michael
Yamani, Secretary